News

Filter

1 to 9 of 32 results

Bristol-Myers Squibb enters global research accord with Calibr

06-01-2015

US pharma major Bristol-Myer Squibb has signed a worldwide research collaboration with the California…

Bristol-Myers SquibbGlobalLicensingPharmaceuticalResearchRespiratory and Pulmonary

NSCLC treatment market set to grow to more than $7.9 billion by 2020

NSCLC treatment market set to grow to more than $7.9 billion by 2020

09-09-2014

The global non-small cell lung cancer treatment market value will increase from $5.1 billion in 2013…

BiotechnologyBoehringer IngelheimBristol-Myers SquibbEli LillyGilotrifGlobalMarkets & MarketingnecitumumabnivolumabOncologyYervoy

Bristol-Myers returns rights to clazakizumab to Alder BioPharma

Bristol-Myers returns rights to clazakizumab to Alder BioPharma

03-09-2014

USA-based drug developer Alder BioPharmaceuticals says it has regained the worldwide rights to clazakizumab,…

Alder BiopharmaceuticalsAnti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbclazakizumabGlobalInflammatory diseasesLicensing

New study identifies potential alternatives to Gilead’s Sovaldi

New study identifies potential alternatives to Gilead’s Sovaldi

29-07-2014

There are multiple hepatitis treatments in development that may serve as potential alternatives to Gilead…

AbbVieAntibiotics and Infectious diseasesBristol-Myers SquibbdaclatasvirGilead SciencesGlobalHepatitis C treatmentMarkets & MarketingmericitabinePharmaceuticalRocheSovaldi

Product launches to fuel lupus market growth

28-02-2014

The systemic lupus erythematosus (SLE) treatment market in the seven major countries (7MM) will increase…

Anti-Arthritics/RheumaticsBenlystaBristol-Myers SquibbEli LillyepratuzumabGlaxoSmithKlineGlobalImmuPharmaLupuzorMerck SeronoOrenciaPharmaceuticalRituxanRochetabalumabUCB

Bayer/Janssen's Xarelto poised to lead sales in VTE market: report

30-08-2013

German drug major Bayer (BAYN: DE) and Johnson & Johnson (NYSE: JNJ) subsidiary Janssen's Xarelto (rivaroxaban)…

BayerBristol-Myers SquibbCardio-vascularEliquisGlobalJanssenJohnson & JohnsonMarkets & MarketingPfizerPharmaceuticalXarelto

Rise in infections means hepatitis C market is expected to peak at $15.5 billion in 2022

27-08-2013

The hepatitis C market is forecast to increase by a massive 230% in the next nine years, according to…

AbbVieAntibiotics and Infectious diseasesBristol-Myers SquibbGilead SciencesGlobalJohnson & JohnsonMarkets & MarketingPharmaceuticalsofosbuvir

B-MS' nivolumab to lead NSCLC market with sales of $1.75 billion by 2022, says GlobalData

08-07-2013

US pharma major Bristol-Myers Squibb's (NYSE: BMY) nivolumab will overtake proven blockbuster competitors…

Bristol-Myers SquibbGlobalMarkets & MarketingnivolumabOncologyPharmaceutical

1 to 9 of 32 results

COMPANY SPOTLIGHT

Menarini

Back to top